Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asiatic LaboratoriesDHA:ASIATICLAB -0.56%32 5-Year Yield-on-Cost % is 0.71 as of Jul. 13, 2026. GuruFocus rates DHA:ASIATICLAB with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 516 Drug Manufacturers companies, Asiatic Laboratories ranks worse than 76.36% on this metric.
Asiatic Laboratories's yield on cost for the quarter that ended in . 20 was 0.71.
The historical rank and industry rank for Asiatic Laboratories's 5-Year Yield-on-Cost % or its related term are showing as below:
DHA:ASIATICLAB'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 2.23
Current: 0.71
During the past 0 years, Asiatic Laboratories's highest Yield on Cost was 2.23. The lowest was 0.00. And the median was 0.00.
DHA:ASIATICLAB's 5-Year Yield-on-Cost % is ranked worse than 76.36% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.245
vs DHA:ASIATICLAB: 0.71
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Asiatic Laboratories 5-Year Yield-on-Cost % Related Terms
DHA:ASIATICLAB vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Asiatic Laboratories's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asiatic Laboratories 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Asiatic Laboratories's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Asiatic Laboratories's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Asiatic Laboratories (DHA:ASIATICLAB) has a 5-Year Yield-on-Cost % of 0.71 as of Jul. 13, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Asiatic Laboratories and its competitors. According to the industry distribution chart, Asiatic Laboratories ranks #394 out of 516 companies in the Drug Manufacturers industry, placing it in the top 76.4%.
Is Asiatic Laboratories' 5-Year Yield-on-Cost % too high?
Asiatic Laboratories' current 5-Year Yield-on-Cost % is 0.71. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.25. Asiatic Laboratories' value of 0.71 is 68.4% below this industry median. Based on the distribution chart, Asiatic Laboratories ranks #394 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Asiatic Laboratories has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Asiatic Laboratories' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Asiatic Laboratories ranks #394 out of 516 companies for 5-Year Yield-on-Cost %. This places Asiatic Laboratories in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.25. Asiatic Laboratories' value of 0.71 is 68.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.25, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asiatic Laboratories's current 5-Year Yield-on-Cost % of 0.71 is 68.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Asiatic Laboratories and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asiatic Laboratories's current 5-Year Yield-on-Cost % is 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asiatic Laboratories stock overvalued right now?
Asiatic Laboratories (DHA:ASIATICLAB) has a current 5-Year Yield-on-Cost % of 0.71. The current 5-Year Yield-on-Cost % is 0.71 and 68.4% below the Drug Manufacturers industry median of 2.25. Asiatic Laboratories' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Asiatic Laboratories (DHA:ASIATICLAB), the current 5-Year Yield-on-Cost % is 0.71 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asiatic Laboratories Ltd is engaged in manufacturing and marketing of a wide range of the rapeutical medicines pharmaceutical products in the categories of Biological, Non-Biological & Sterile Pharmaceutical dosage. It has 80 generic molecules comprising therapeutic classes like antibiotics, antihistamines, bronchodilators, vitamins-minerals, antiulcerants, laxatives, gastroprokinetics, antihematinic, anthelmentics, CNS drugs, respiratory drugs, NSAIDs, dermatological preparations and sterile ophthalmic preparations.
32GF Score
Get the complete analysis for DHA:ASIATICLAB
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ASIATICLAB has been successfully added to your 
